Validation Data Gallery
Filter:
Tested Applications
| Positive FC detected in | Con-A treated human PBMCs |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
PE-98112 targets TNFRSF9/CD137 in FC applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | Recombinant Protein 相同性解析による交差性が予測される生物種 |
| Full Name | tumor necrosis factor receptor superfamily, member 9 |
| Calculated molecular weight | 28 kDa |
| GenBank accession number | BC006196 |
| Gene Symbol | TNFRSF9/CD137 |
| Gene ID (NCBI) | 3604 |
| Conjugate | PE Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 496 nm, 565 nm / 578 nm |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | Q07011 |
| Storage Buffer | PBS with 0.09% sodium azide and 0.5% BSA , pH 7.3 |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
CD137, also known as TNFRSF9 or 4-1BB, is an inducible T cell surface receptor that belongs to the tumor necrosis factor receptor superfamily. CD137 is a transmembrane protein expressed on the surface of activated T-cells. In addition, activation-dependent expression of CD137 has also been found in B lymphocytes, monocytes, and diverse nonlymphoid cell types. CD137 provides a co-stimulatory signal that enhances the survival, and differentiation of cells, and has a crucial role in the development of CD8 cytotoxic T cells and anti-tumor immunity. (PMID: 9826581; 23696891)
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for PE TNFRSF9/CD137 antibody PE-98112 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |